Coenzyme Q10




Test Mnemonic

COEQ10

CPT Codes

  • 82542 - QTY (1)

Includes

  • Coenz Q10 Reduced
  • Coenz Q10 % Reduced
  • Coenzyme Q10 Total

Performing Laboratory

Mayo Clinic Dpt of Lab Med & Pathology


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.5 mLPlasmaSodium or Lithium heparin (Green)N/APlace specimen on ice after draw.Remove plasma from cells within 3 hours and freeze. Collect Monday - Thursday only. Patient should fast for 8 hours pior to collection. Transport frozen.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
0.3 mL     

Stability

Environmental Condition Description
Frozen14 days
Refrigerated8 hours
AmbientUnacceptable

Days Performed

Varies

Turnaround Time

4 - 8 days

Methodology

Name Description
High Performance Liquid Chromatography with Electrochemical Detection 

Reference Range

Coenz Q10 % Reduced
Sex Age From Age To Type Range Range Unit
   Years17 YearsNormal93 - 100%
 18 Years99 YearsNormal92 - 98%
Coenz Q10 Reduced
Sex Age From Age To Type Range Range Unit
   Years17 YearsNormal320 - 1376mcg/L
 18 Years99 YearsNormal415 - 1480mcg/L
Coenzyme Q10 Total
Sex Age From Age To Type Range Range Unit
   Years17 YearsNormal320 - 1558mcg/L
 18 Years99 YearsNormal433 - 1532mcg/L

Special Info

Freeze plasma within 3 hours of collection. Failure to follow specimen handling guidelines may lead to false positive results. Hemolyzed, lipemic and grossly icteric specimens will be rejected.

Clinical Info

Potential indications for testing coenzyme Q10 status include: Suspected coenzyme Q10 deficiency secondary to inheritance or other mitochondrial disease, cardiomyopathy, neurodegenerative diseases (Parkinson's, Alzheimer's, muscular dystrophy, ALS), metabolic disease, malnutrition, presurgical screening for patient who have pre-existing coenzyme Q10 deficiency or who may have increased risk of ischemia-reperfusion injury, prior treatment with HMG-CoA reductase inhibitors ('statin' drugs) or other drugs which may lower coenzyme Q10 levels, gastrointestinal malabsorption, and assessment of coenzyme Q10 dosing adequacy.